Mishal A Altamimi
SFDA, Saudi Arabia
Scientific Tracks Abstracts: Pharmaceut Reg Affairs
Pharmaceuticals, cosmetics, medical device and food were scattered between different government organizations before the establishments of the Saudi Food and Drug Authority (SFDA) in 2004. It took the SFDA about ten years to take all the responsibility in these years the SFDA built the infra-structure and invest heavily in the training and education by sending its young generation employee to the best universities in the west. Also during this time a lot of laws, regulations and guidelines based on best international practices were written and went through the approval processes. One of these laws is the cosmetics law which is in the final stages of the approval processes. The cosmetics law will be the first in the region, and Saudi Arabia will be the first to have a comprehensive law covering all aspects of cosmetics regulations, to cover the huge market of cosmetic products which is around 2 billion dollar; some of these products are manufactured locally and some are imported from all over the world, with a market open the necessity for a good regulatory system. a system that will control the cosmetic product at the points of entry (borders) as well as in the local manufacturers until it reaches the consumer by establishing a good notification system, cosmovigilance, developing cosmetic products safety guidelines and establishing good labs that will analyze the product to be sure it fits the standards and no hazardous material been used. In this presentation all aspects of cosmetic regulations in Saudi Arabia will be discussed.
Mishal A Altamimi is a pharmacist graduate from the college of pharmacy King Saud University Riyadh Saudi Arabia in 2002 and got a master degree in health administration from King Saud University Riyadh Saudi Arabia in 2007 he joined the SFDA in 2006. He worked in several positions including the pharmaceutical license department and now is the director of the Department of the cosmetics department.
Pharmaceutical Regulatory Affairs: Open Access received 471 citations as per Google Scholar report